We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

56 hedge funds and large institutions have $295M invested in Kiniksa Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

520% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 5

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

8.41% more ownership

Funds ownership: 79.15% → 87.56% (+8.4%)

8% more funds holding

Funds holding: 52 → 56 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

24% less capital invested

Capital invested by funds: $385M → $295M (-$90.6M)

Holders
56
Holders Change
+4
Holders Change %
+7.69%
% of All Funds
1.21%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
31
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
ACH
ArrowMark Colorado Holdings
Colorado
+$31.1M
2
VC
Vivo Capital
California
+$11.2M
3
HA
HHLR Advisors
Cayman Islands
+$8.63M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$6.53M
5
BlackRock
BlackRock
New York
+$6.24M

Top Sellers

1
CAM
Cormorant Asset Management
Massachusetts
-$10.8M
2
Millennium Management
Millennium Management
New York
-$1.46M
3
Invesco
Invesco
Georgia
-$1.25M
4
AG
Algert Global
California
-$300K
5
AllianceBernstein
AllianceBernstein
Tennessee
-$247K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$54.2M – – –
HA
2
HHLR Advisors
Cayman Islands
$33.2M +$8.63M +447,000 +32%
ACH
3
ArrowMark Colorado Holdings
Colorado
$29.1M +$31.1M +1,610,181 New
DM
4
Deerfield Management
New York
$23.7M +$3.5M +181,437 +16%
Vanguard Group
5
Vanguard Group
Pennsylvania
$22.5M +$6.53M +337,951 +37%
BlackRock
6
BlackRock
New York
$17.5M +$6.24M +322,908 +50%
SI
7
Sofinnova Investments
California
$16.7M – – –
VC
8
Vivo Capital
California
$15.2M +$11.2M +578,600 +218%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$11.5M – – –
VMI
10
VHCP Management II
New York
$11.5M – – –
Ameriprise
11
Ameriprise
Minnesota
$9.66M +$4.48M +231,985 +77%
VMI
12
VHCP Management III
New York
$5.92M – – –
EAM
13
Eventide Asset Management
Massachusetts
$5.76M – – –
BC
14
Boxer Capital
California
$5.25M – – –
CAM
15
Cormorant Asset Management
Massachusetts
$4.88M -$10.8M -561,000 -68%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$2.71M +$1.03M +53,345 +55%
Northern Trust
17
Northern Trust
Illinois
$2.39M +$1.04M +53,670 +68%
Alyeska Investment Group
18
Alyeska Investment Group
Illinois
$2.38M +$2.54M +131,502 New
State Street
19
State Street
Massachusetts
$2.28M +$860K +44,499 +54%
Citadel Advisors
20
Citadel Advisors
Florida
$2.27M +$1.73M +89,628 +247%
D.E. Shaw & Co
21
D.E. Shaw & Co
New York
$1.72M +$1.66M +85,714 +898%
Hudson Bay Capital Management
22
Hudson Bay Capital Management
Connecticut
$1.63M +$1.74M +90,000 New
Victory Capital Management
23
Victory Capital Management
Texas
$1.53M -$18.2K -940 -1%
SIM
24
Spark Investment Management
New York
$1.22M +$922K +47,727 +239%
NC
25
Nexthera Capital
New York
$1.22M +$1.31M +67,692 New
1
2 3

KNSA Hedge Fund Activity: Q1 2019 in Review

56 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2019, worth a combined $295M — down 24% from $385M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new KNSA positions and 5 closed out — a net gain of 4 holders — while 31 added to existing stakes and 5 trimmed.

The largest buyer was ArrowMark Colorado Holdings, opening a new position worth an estimated $31.1M. The largest seller was Cormorant Asset Management, cutting an estimated $10.8M.

  • 56 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2019, up from 52 in Q4 2018.
  • Funds reported $295M of Kiniksa Pharmaceuticals stock for Q1 2019, down 24% quarter-over-quarter.
  • 9 funds opened new Kiniksa Pharmaceuticals positions in Q1 2019 and 5 closed out, a net change of +4 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q1 2019 was ArrowMark Colorado Holdings, an estimated $31.1M added.
  • The largest Kiniksa Pharmaceuticals seller in Q1 2019 was Cormorant Asset Management, an estimated $10.8M sold.

Based on aggregated 13F filings for Q1 2019.